We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-7.32%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.93B
AUM Growth
-$321M
(-14%)
Cap. Flow
-$98.8M
Cap. Flow
% of AUM
-5.11%
Top 10 Holdings %
Top 10 Hldgs %
70.83%
Holding
57
New
3
Increased
7
Reduced
11
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$153M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$19.4M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$5.75M |
| 4 |
Pharvaris
PHVS
|
+$5.27M |
| 5 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$4.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$61.5M |
| 2 |
Harmony Biosciences
HRMY
|
+$44.5M |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$36M |
| 4 |
INZY
Inozyme Pharma
INZY
|
+$31.8M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$26.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.28% |
| 2 | Financials | 8.56% |
| 3 | Technology | 7.59% |
| 4 | Consumer Discretionary | 1.65% |
| 5 | Communication Services | 1.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
51
DELISTED
Inozyme Pharma
INZY
| – | – |
-1,867,706
| Closed | -$31.8M |
|
52
Legend Biotech
LEGN
$4.01B
| – | – |
-279,676
| Closed | -$11.5M |
|
|
53
Protagonist Therapeutics
PTGX
$9.44B
| – | – |
-600,010
| Closed | -$26.9M |
|
|
BNT
54
Brookfield Wealth Solutions
BNT
$12.2B
| – | – |
-31,769
| Closed | -$1.1M |
|
|
EAR
55
DELISTED
Eargo, Inc. Common Stock
EAR
| – | – |
-11,854
| Closed | -$9.46M |
|
|
XENT
56
DELISTED
Intersect ENT, Inc
XENT
| – | – |
-508,922
| Closed | -$8.7M |
|
|
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-53,300
| Closed | -$5.17M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q3 2021 Portfolio in Review
As of Q3 2021, Novo Holdings A/S held 57 positions worth $1.93B, down 14% from $2.25B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Novo Holdings A/S withdrew a net $98.8M in Q3 2021, closing 8 positions and reducing 11 holdings. Its most notable exit was Inozyme Pharma, an estimated $31.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 61% a quarter earlier, followed by Financials and Technology.
Against the trend, Novo Holdings A/S opened a new position in Boston Scientific worth $150M.
- Novo Holdings A/S's largest Q3 2021 buy was Boston Scientific: 3,463,577 shares worth $150M.
- Novo Holdings A/S added most to Amicus Therapeutics in Q3 2021, an estimated $5.75M increase.
- Novo Holdings A/S's biggest Q3 2021 reduction was Inogen, cutting an estimated $61.5M.
- Novo Holdings A/S fully exited Inozyme Pharma in Q3 2021, selling an estimated $31.8M.
- Novo Holdings A/S's ten largest holdings make up 71% of its $1.93B portfolio in Q3 2021.
- Novo Holdings A/S opened 3 new positions and closed 8 in Q3 2021.
- Novo Holdings A/S's portfolio value fell 14% quarter-over-quarter to $1.93B.
Based on Novo Holdings A/S's 13F filing for Q3 2021, filed 15 Nov 2021.